Triple Incretin Agonists in Diabetes Mellitus: Retatrutide Improves Lipid Profile and Decreases Blood Pressure
Saved in:
Main Authors: | Nuri Barış Hasbal, Çiçek Nur Bakır, Sidar Çopur, Mehmet Kanbay |
---|---|
Format: | Article |
Language: | English |
Published: |
AVES
2025-01-01
|
Series: | Turkish Journal of Nephrology |
Online Access: | https://turkjnephrol.org/en/triple-incretin-agonists-in-diabetes-mellitus-retatrutide-improves-lipid-profile-and-decreases-blood-pressure-137226 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Impact of Incretin-Based Medications on Lipid Metabolism
by: Habib Yaribeygi, et al.
Published: (2021-01-01) -
Impact of Incretin-Based Therapies on Adipokines and Adiponectin
by: Habib Yaribeygi, et al.
Published: (2021-01-01) -
Beyond incretins: targeting neurokinin receptors for obesity treatment
by: Doreen Thor, et al.
Published: (2025-01-01) -
Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
by: Jae Hyun Bae, et al.
Published: (2025-02-01) -
The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
by: Jakub Waszczyński, et al.
Published: (2025-01-01)